Real-World Insights on Biomarker Testing Patterns and Implications for mNSCLC Therapy Selection
AJMC,
Author(s)Amy Stanford, PharmD, Shawn Boykin, PhD, Karishma Desai, PhD, MS, BPharm Listen 0:00 / 0:00 Key Takeaways Most…
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
OncLive,
In treating patients with locally advanced non–small cell lung cancer, one must consider multiple factors when deciding whether…
PD-L1 Status Stratifies Immunotherapy Treatment in NSCLC
OncLive,
The therapeutic landscape for first-line treatment of metastatic non–small cell lung cancer (NSCLC) contains many options.
Piotrowska Addresses Immunotherapy Treatment in NSCLC With Mutations
Medical Health News,
During a virtual Case Based Peer Perspective series, Zofia Piotrowska, MD, assistant professor,Harvard Medical School…